Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · IEX Real-Time Price · USD
5.00
-0.04 (-0.89%)
Jul 22, 2024, 9:37 AM EDT - Market open
Marker Therapeutics Employees
Marker Therapeutics had 8 employees as of December 31, 2023. The number of employees decreased by 59 or -88.06% compared to the previous year.
Employees
8
Change (1Y)
-59
Growth (1Y)
-88.06%
Revenue / Employee
$415,107
Profits / Employee
-$707,758
Market Cap
45.75M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Qilian International Holding Group | 298 |
Carisma Therapeutics | 107 |
Lucid Diagnostics | 70 |
Kezar Life Sciences | 58 |
Elicio Therapeutics | 32 |
Matinas BioPharma Holdings | 32 |
Protara Therapeutics | 27 |
Regencell Bioscience Holdings | 12 |
MRKR News
- 2 months ago - Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies - GlobeNewsWire
- 4 months ago - Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results - GlobeNewsWire
- 4 months ago - Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference - GlobeNewsWire
- 6 months ago - Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 - GlobeNewsWire
- 7 months ago - Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization - GlobeNewsWire
- 7 months ago - Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” - GlobeNewsWire
- 9 months ago - Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates - GlobeNewsWire